Memgen
Houston, US · Delaware corporation
Memgen develops viral, cell-based, and vaccine adjuvant immunotherapies built on its proprietary CD40 ligand technology for treating cancer. Its lead candidate, MEM-288, combines the CD40 ligand with interferon beta and is in phase 1 clinical trials for advanced non-small cell lung cancer.
Founders & leadership
RC
Robert CoatesExecutive
GB
Gregory BrownExecutive
MC
Mark CantwellNamed on SEC filing
Board
PB
Patricia BitarBoard director
CP
Christopher PaganoBoard director
SW
Steven WhitleyBoard director
CL
Casey LoganBoard director
JP
John PoulosBoard director
Reported raises · per SEC filings
Form D private placements$13M disclosed across 6 rounds · 2018–2024
▶$950KraisedDec 2024 · 2 investors · BiotechnologyRule 506(b)
▶$950KraisedDec 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patricia BitarDirector
- Mark CantwellExecutive Officer
- Christopher PaganoDirector
- Robert CoatesExecutive Officer, Director
- Steven WhitleyDirector
- Gregory BrownExecutive Officer, Director
- Casey LoganDirector
- John PoulosDirector
- Offering amount
- $10M
- Amount sold
- $950K
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$625KraisedJun 2023 · 8 investors · BiotechnologyRule 506(b)
▶$625KraisedJun 2023 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven WhitleyDirector
- Christopher PaganoDirector
- Patricia BitarDirector
- Mark CantwellExecutive Officer
- John PoulosDirector
- Gregory BrownExecutive Officer, Director
- Robert CoatesExecutive Officer, Director
- Casey LoganDirector
- Offering amount
- $10M
- Amount sold
- $625K
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.8MraisedDec 2021 · 60 investors · BiotechnologyRule 506(b)
▶$9.8MraisedDec 2021 · 60 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patricia BitarDirector
- Christopher PaganoDirector
- Steven WhitleyDirector
- Kevin CoveneyExecutive Officer
- John PoulosDirector
- Gregory BrownExecutive Officer, Director
- Mark CantwellExecutive Officer, Director
- Robert CoatesExecutive Officer, Director
- Casey LoganDirector
- Offering amount
- $10M
- Amount sold
- $9.8M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$575KraisedJul 2020 · 7 investors · BiotechnologyRule 506(b)
▶$575KraisedJul 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Casey LoganDirector
- Gregory BrownExecutive Officer, Director
- Christopher PaganoDirector
- Robert CoatesExecutive Officer, Director
- Patricia BitarDirector
- Mark CantwellExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $575K
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$350KraisedSep 2019 · 3 investors · BiotechnologyRule 506(b)
▶$350KraisedSep 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patricia BitarDirector
- Gregory BrownDirector
- Robert CoatesExecutive Officer, Director
- Mark CantwellExecutive Officer, Director
- Casey LoganDirector
- Offering amount
- $5M
- Amount sold
- $350K
- Proceeds to insiders
- $360K
- First sale
- Sep 2019
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$715KraisedDec 2018 · 10 investors · BiotechnologyRule 506(b)
▶$715KraisedDec 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert CoatesExecutive Officer, Director
- Mark CantwellExecutive Officer, Director
- Gregory BrownDirector
- Casey LoganDirector
- Offering amount
- $1.9M
- Amount sold
- $715K
- Minimum investment
- $10K
- First sale
- Nov 2018
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Biogen Idec11 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Amgen9 shared keywordsAmgen develops therapies based on biotechnology and scientific research aimed at treating patients and improving or saving lives. It operates in the biopharmaceutical industry, moving discoveries from the laboratory through clinical development to market.
Metagenomi7 shared keywordsMetagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations. It focuses on developing genetic medicines to treat diseases with well-understood biology.
Regeneron NASDAQ: REGN www.regeneron.com7 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Companies competing with Memgen for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Memgen do?
- Memgen develops viral, cell-based, and vaccine adjuvant immunotherapies built on its proprietary CD40 ligand technology for treating cancer. Its lead candidate, MEM-288, combines the CD40 ligand with interferon beta and is in phase 1 clinical trials for advanced non-small cell lung cancer.
- How much funding has Memgen raised?
- Memgen has disclosed $13M raised across 6 rounds.
- Where is Memgen headquartered?
- Memgen is headquartered in Houston, US.